Skip to main content

Advertisement

SpringerLink
Log in

Optimal treatment opportunity for mTHPC-mediated photodynamic therapy of liver cancer

  • Original Article
  • Published:
Lasers in Medical Science Aims and scope Submit manuscript

Abstract

Photodynamic therapy (PDT) has been clinically used for liver cancer. The pharmacokinetics of a photosensitizer needs to be monitored so that PDT can be performed at the most favorable time and with the proper dose to increase the cure rate. As mTHPC is a fluorescent compound, we investigate its pharmacokinetics, distribution, and elimination in the rat orthotropic liver cancer model in order to confirm an optimal treatment opportunity of liver cancer PDT. After intravenous administration at a single dose of 300 μg/kg, mTHPC was extracted from tissue homogenates or plasma. Then, mTHPC concentrations were assessed by fluorescence spectroscopy and the data were processed with PK-GRAPH pharmacokinetic procedure. The plasma concentration–time profile of mTHPC showed a short distribution half-life (T½α = 0.082 h) and a relatively longer elimination half-life (T½β = 28.23 h), which quite fitted with a two-compartment model. The results of mTHPC tissue distributions showed that the highest drug accumulation was in tumor tissue, and successively decreased in liver, heart, spleen, muscle, and skin tissues. The drug distribution ratio of tumor to normal tissue reached the peak at 24 h after mTHPC administration. mTHPC was eliminated at a suitable rate in rat orthotropic liver cancer model, and there was no long-term accumulation of mTHPC in rat tissues. For PDT of orthotropic liver cancer, 24 h after mTHPC intravenous injection may be the optimal treatment time point, which might provide higher clinical efficacy and reduce side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Bosch FX, Ribes J, Diaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 Suppl 1):S5–S16

    Article  PubMed  Google Scholar 

  2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics. CA Cancer J Clin 55:10–30

    Article  PubMed  Google Scholar 

  3. Huang Z, Xu H, Meyers AD, Musani AI, Wang L, Tagg R, Barqawi AB, Chen YK (2008) Photodynamic therapy for treatment of solid tumors: potential and technical challenges. Technol Cancer Res Treat 7:309–320

    PubMed  CAS  Google Scholar 

  4. Huang Z (2006) Photodynamic therapy in China: 25 years of unique history—part two: clinical experience. Photodiagnosis Photodyn Ther 3:71–84

    Article  CAS  Google Scholar 

  5. Chen B, Xu Y, Roskams T, Delaey E, Agostinis P, Vandenheede JR, de Witte P (2001) Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int J Cancer 93:275–282

    Article  PubMed  CAS  Google Scholar 

  6. Gossner L, Stolte M, Seitz G, Hahn EG, Stewart C, Ell C (1996) mTHPC for photodynamic therapy of early gastric cancer [abstract]. Gastroenterology 110:A521

    Google Scholar 

  7. Lovat LB, Whitelaw DE, Spencer GM, Thorpe SM, Mlkvy PP, Buonaccorsi G, Bown SG (1999) Photodynamic therapy for gastrointestinal tumours using mTHPC [abstract]. Gastroenterology 116:A456

    Google Scholar 

  8. Fan K, Hopper C, Speight P, Bown S (1996) Photodynamic therapy using a new photosensitiser, mTHPC, in the treatment of oral cancer. J Dental Res 75:1164

    Google Scholar 

  9. Garrier J, Bressenot A, Gräfe S, Marchal S, Mitra S, Foster TH, Guillemin F (2010) Compartmental targeting for mTHPC based photodynamic treatment in vivo: correlation between efficiency, pharmacokinetics and regional distribution of apoptosis. Int J Radiat Oncol Biol Phys 78:563–571

    Article  PubMed  CAS  Google Scholar 

  10. Kascáková S, Kruijt B, de Bruijn HS, van der Ploeg-van den Heuvel A, Robinson DJ, Sterenborg HJ, Amelink A (2008) Ex vivo quantification of mTHPC concentration in tissue: influence of chemical extraction on the optical properties. J Photochem Photobiol B 91(2–3):99–107, 91

    Article  PubMed  Google Scholar 

  11. Lilge L, O’Carroll C, Wilson BC (1997) A solubilization technique for photosensitizer quantification in ex vivo tissue samples. J Photochem Photobiol B 39:229–235

    Article  PubMed  CAS  Google Scholar 

  12. Chen JY, Mak NK, Yow CM, Fung MC, Chiu LC, Leung WN, Cheung NH (2000) The binding characteristics and intracellular localization of temoporfin (mTHPC) in myeloid leukemia cells: phototoxicity and mitochondrial damage. Photochem Photobiol 72:541–547

    Article  PubMed  CAS  Google Scholar 

  13. Glanzmann T, Hadjur C, Zellweger M, Grosiean P, Forrer M, Ballini JP, Monnier P, Van den Bergh H, Lim CK, Wagnieres G (1998) Pharmacokinetics of tetra(m-hydroxyphenyl) chlorin in human plasma and individualized light dosimetry in photodynamic therapy. Photochem Photobiol 67:596–602

    PubMed  CAS  Google Scholar 

  14. Jones HJ, Vernon DI, Brown SB (2003) Photodynamic therapy effect of mTHPC (Foscan) in vivo: correlation with pharmacokinetics. Br J Cancer 89:398–404

    Article  PubMed  CAS  Google Scholar 

  15. Cramers P, Ruevekamp M, Oppelaar H, Dalesio O, Baas P, Stewart FA (2003) Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer 88:283–290

    Article  PubMed  CAS  Google Scholar 

  16. Lassalle HP, Dumas D, Gräfe S, D’Hallewin MA, Guillemin F, Bezdetnaya L (2009) Correlation between in vivo pharmacokinetics, intratumoral distribution and photodynamic efficiency of liposomal mTHPC. J Control Release 134(2):118–124

    Article  PubMed  CAS  Google Scholar 

  17. Ronn AM, Batti J, Lee CJ, Yoo D, Siegel ME, Nouri M, Lofgren LA, Steinberg BM (1997) Comparative biodistribution of meta-tetra(hydroxyphenyl)chlorin in multiple species: clinical implications for photodynamic therapy. Lasers Surg Med 20(4):437–442

    Article  PubMed  CAS  Google Scholar 

  18. Campbell GA, Bartels KE, Arnold C, Healey T, Cowell RL, Lucroy MD, Ronn AM (2002) Tissue levels, histologic changes and plasma pharmacokinetics of meta-tetra (hydroxyphenyl) chlorin (mTHPC) in the cat. Lasers Med Sci 17(2):79–85

    Article  PubMed  CAS  Google Scholar 

  19. Obwegeser A, Jakober R, Kostron H (1998) Uptake and kinetics of 14C-labelled meta-tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat glioma model. Br J Cancer 78:733–738

    Article  PubMed  CAS  Google Scholar 

  20. Rovers JP, Saarnak AE, de Jode M, Sterenborg HJ, Terpstra OT, Grahn MF (2000) Biodistribution and bioactivity of tetra-pegylated meta-tetra(hydroxyphenyl)chlorin compared to native meta-tetra(hydroxyphenyl)chlorin in a rat liver tumor model. Photochem Photobiol 71(2):211–217

    Article  PubMed  CAS  Google Scholar 

  21. Rovers JP, de Jode ML, Grahn MF (2000) Significantly increased lesion size by using the near-infrared photosensitizer 5,10,15,20-tetrakis (m-hydroxyphenyl)bacteriochlorin in interstitial photodynamic therapy of normal rat liver tissue. Lasers Surg Med 27:235–240

    Article  PubMed  CAS  Google Scholar 

  22. Whelpton R, Michael-Titus AT, Basra SS, Grahn M (1995) Distribution of temoporfin, a new photosensitizer for the photodynamic therapy of cancer, in a murine tumor model. Photochem Photobiol 61:397–401

    Article  PubMed  CAS  Google Scholar 

  23. Veenhuizen RB, Ruevekamp MC, Oppelaar H, Helmerhorst TJ, Kenemans P, Stewart FA (1997) Foscan-mediated photodynamic therapy for a peritoneal-cancer model: drug distribution and efficacy studies. Int J Cancer 73(2):230–235

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the National “Eleventh Five-Year” special science and technology major project (no. 2008ZX10002-025) and the College Fund of Shanghai Jiaotong University School of Medicine (no. 10XJ22003).

Conflict of Interest

None

Author information

Authors and Affiliations

  1. Department of General Surgery, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, No. 1665, Kongjiang Road, Shanghai, 200092, China

    Jian-dong Wang, Jun Shen, Xue-ping Zhou, Wei-bin Shi & Zhi-wei Quan

  2. Anti-cancer Research Center affiliated to Xiamen University School of Medicine, Xiamen, 361005, China

    Jiang-hua Yan & Fang-hong Luo

Authors
  1. Jian-dong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xue-ping Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei-bin Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiang-hua Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fang-hong Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhi-wei Quan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhi-wei Quan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Jd., Shen, J., Zhou, Xp. et al. Optimal treatment opportunity for mTHPC-mediated photodynamic therapy of liver cancer. Lasers Med Sci 28, 1541–1548 (2013). https://doi.org/10.1007/s10103-012-1248-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10103-012-1248-3

Keywords

Search

Navigation